Previous studies have reported that the FGFR2 protein was overexpressed by immunohistrochemistry (IHC) in 30-40% of gastric cancer patients undergoing curative resection [33, 34], although the incidence of FGFR2 gene amplification was only 4-10 % in cases of resectable gastric cancer [21–23, 26, 35] and 4.4-11.5% in cases of unresectable gastric cancer [31, 32]. The gene discussed is FGFR2; the disease is gastric cancer.